Lonza Capabilities Update October 2026: Large Molecule

As patient demand for biologics keeps growing and next-generation biologics pipelines continue to diversify, commercial manufacturing strategies must balance broad biologics capabilities with speed, flexible scaling, end-to-end services and long-term supply security.

In this Outsourced Pharma Capacity Update, Ben Neunstoecklin, Director, Commercial Development at Lonza, provides an overview of Lonza's biologics drug substance manufacturing capabilities and global network capacity that supports customer programs from development through commercial supply.